Advertisement
Review| Volume 3, ISSUE 1, P17-21, January 2014

Download started.

Ok

Sustained-release fampridine in Multiple Sclerosis

  • S. Hadavi
    Affiliations
    Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Search for articles by this author
  • M.D. Baker
    Affiliations
    Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Search for articles by this author
  • R. Dobson
    Correspondence
    Correspondence to: Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London E1 2AT, UK. Tel.: +44 207 882 2285; fax: +44 207 882 2180.
    Affiliations
    Blizard Institute, Queen Mary University of London, Barts and the London School of Medicine and Dentistry, London, UK
    Search for articles by this author
Published:July 08, 2013DOI:https://doi.org/10.1016/j.msard.2013.06.003
Sustained-release fampridine in Multiple Sclerosis
Previous ArticleVision and multiple sclerosis
Next ArticleA review of the anterior visual pathway model and the study of vitamin D in demyelinating disease

      Highlights

      • •
        Fampridine is licensed for the improvement of walking disability in MS patients with an EDSS of 4–7.
      • •
        30% of patients respond to the drug.
      • •
        Meaningful improvement in both walking speed and patients' subjective perception of their ambulatory deficits is demonstrated using fampridine 10 mg twice-daily.
      • •
        Clinical differentiation of responders from non-responders either by stage of disease or lesion location is not yet possible.
      • •
        Fampridine has an acceptable adverse event profile.

      Abstract

      Sustained-release fampridine, a slow release formulation of 4-aminopryridine, is a voltage-dependent potassium channel blocker licensed for the treatment of walking difficulties in multiple sclerosis (MS). Studies have demonstrated that approximately one-third of MS patients respond with a clear benefit to their walking speed.
      Sustained-release Fampridine is not currently available on the National Health Service (NHS), although it has been approved by the Food and Drug Administration (FDA) in the USA and European Medicine Agency (EMA). It appears to have an acceptable adverse event profile, with data from open-label extension studies now becoming available. Concerns have been raised that the use of fampridine may increase the risk of seizures, which were seen at higher rates in patients treated with high doses of sustained-release fampridine. The rate of seizures in those patients on lower doses has not been found to be significantly increased. There are significant barriers at present to the widespread use of fampridine in the UK, which have limited its use in clinical practice to date.
      Patients with MS are in need of interventions to improve walking and many clinicians feel that this drug may have a role in the symptomatic management of MS.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

      1. Baker, MD. Potential therapeutic mechanism of K+ channel block for MS. Multiple Sclerosis and Related Disorders, 10.1016/j.msard.2013.01.005, in press

        View in Article
        • Bever Jr, CT
        • Young D
        • Anderson PA
        • et al.
        The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-åcontrolled, crossover trial.
        Neurology. 1994; 44: 1054-1059
        View in Article
        • Chaplin S
        • Dobson R.
        Fampridine for the improvement of walking in multiple sclerosis.
        Prescriber. 2012; 23: 12-16
        View in Article
        • Coles A.
        Multiple sclerosis.
        Practical Neurology. 2009; 9: 118-126
        View in Article

      5. Cuccurullo S. Gait analysis: physical medicine and rehabilitation board review 2004. NCBI bookshelf. Available from: 〈http://www.ncbi.nlm.nih.gov/books/NBK27235/〉; 2012 [accessed 5.07.12].

        View in Article
        • Dalgas U
        • Severinsen K
        • Overgaard K.
        Relations between 6 min walking distance and 10 m walking speed in patients with multiple sclerosis and stroke.
        Archives of Physical Medicine and Rehabilitation. 2012 Jul; 93: 1167-1172
        View in Article

      7. European Medicines Agency. Refusal of the marketing authorisåation for Fampyra (fampridine). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_Initial_authorisation/human/002097/WC500101071.pdf; 2013 [accessed 03.03.13].

        View in Article

      8. Food and Drug Administration. NDA: 22–250 Fampridine AC Background. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM185663.pdf;2013 [accessed 03.03.13].

        View in Article

      9. Food and Drug Administration. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM191029.pdf;2013 [accessed 03.03.13].

        View in Article
        • Goodman AD
        • Brown TR
        • Cohen JA
        • Krupp LB
        • Schapiro R
        • Schwid SR
        • et al.
        Fampridine MS-F202 Study Group. Dose comparison trial of sustained-release fampridine in multiple sclerosis.
        Neurology. 2008; 71: 1134-1141
        View in Article
        • Goodman AD
        • Brown TR
        • Edwards KR
        • Krupp LB
        • Schapiro RT
        • Cohen R
        • et al.
        MSF204 Investigators. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
        Annals of Neurology. 2010; 68: 494-502
        View in Article
        • Goodman AD
        • Brown TR
        • Krupp LB
        • Schapiro RT
        • Schwid SR
        • Cohen R
        • et al.
        Fampridine MS-F203 Investigators. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
        Lancet. 2009; 373: 732-738
        View in Article
        • Goodman AD
        • Cohen JA
        • Cross A
        • Vollmer T
        • Rizzo M
        • Cohen R
        • et al.
        Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study.
        Multiple Sclerosis. 2007; 13: 357-368
        View in Article
        • Heesen C
        • Bohm J
        • Reich C
        • Kasper J
        • Goebel M
        • Gold SM.
        Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable.
        Multiple Sclerosis. 2008; 14: 988-991
        View in Article
        • Hersh C
        • Rae-Grant A.
        Extended-release dalfampridine in the management of multiple-sclerosis-related walking impairment.
        Therapeutic Advances in Neurological Disorders. 2012; 5: 199-204
        View in Article
        • Hobart J
        • Lamping D
        • Fitzpatrick R
        • Riazi A
        • Thompson A.
        The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
        Brain. 2001; 124: 962-973
        View in Article
        • Koch M
        • Uyttenboogaart M
        • Polman S
        • De Keyser J.
        Seizures in multiple sclerosis.
        Epilepsia. 2008; 49: 948-953
        View in Article
        • Larson RD
        • Larson DJ
        • Baumgartner TB
        • White LJ.
        Repeatability of the timed 25-foot walk test for individuals with multiple sclerosis.
        Clinical Rehabilitation. 2013; ([Epub ahead of print])
        View in Article
        • Murray NM
        • Newsom-Davis J.
        Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission.
        Neurology. 1981; 31: 265-271
        View in Article

      20. NICE. Management of multiple Sclerosis in primary and secondary care. National Institute for Health and Clinical Excellence 2008, London. Available from: 〈http://www.nice.org.uk〉; 2012 [accessed 5.07.12].

        View in Article

      21. North East Treatment Advisory Group. Fampridine (Fampyra®) in multiple sclerosis. 〈http://www.netag.nhs.uk/files/appraisalreports/Fampridine%20in%20MS%20%20NETAG%20appraisal%20report%20-Mar2012.pdf〉;2013 [accessed 03.03.13].

        View in Article
        • Phan-Ba R
        • Calay P
        • Grodent P
        • Delrue G
        • Lommers E
        • Delvaux V
        • et al.
        A corrected version of the Timed-25 Foot Walk Test with a dynamic start to capture the maximum ambulation speed in multiple sclerosis patients.
        Neurorehabilitation. 2012; 30: 261-266
        View in Article
        • Remelius JG
        • Jones SL
        • House JD
        • Busa MA
        • Averill JL
        • Sugumaran K
        • et al.
        Gait impairments in persons with multiple sclerosis across preferred and fixed walking speeds.
        Archives of Physical Medicine and Rehabilitation. 2012; 93: 1637-1642
        View in Article
        • Schwid SR
        • Petrie MD
        • McDermott MP
        • Tierney DS
        • Mason DH
        • Goodman AD.
        Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
        Neurology. 1997; 48: 817-821
        View in Article
        • Snappin SM
        • Jiang Q.
        Responder analyses and the assessment of a clinically relevant treatment effect.
        Trials. 2007; 8: 31
        View in Article
        • Swingler RJ
        • Compston DA.
        The morbidity of multiple sclerosis.
        Quarterly Journal of Medicine. 1992; 83: 325-337
        View in Article

      Article info

      Publication history

      Published online: July 08, 2013
      Accepted: June 3, 2013
      Received in revised form: May 30, 2013
      Received: November 2, 2012

      Identification

      DOI: https://doi.org/10.1016/j.msard.2013.06.003

      Copyright

      © 2013 Elsevier B.V. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX